13S131: COVID "Lemonade": Lessons Beyond the Disruption of the Pandemic

Sunday, November 13, 2022

12:00 PM – 1:00 PM Eastern Time

Location: Room 113

CE: 1

All of the relevant financial relationships listed for faculty have been mitigated.

Moderator(s)

Minna Kohler, MD, RhMSUS

Massachusetts General Hospital, Harvard Medical School
Boston, MA, United States

Disclosure(s): Lilly: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, December 1, 2020); Mymee: Consultant (Ongoing); Novartis: Consultant (Terminated, November 1, 2020); Setpoint Medical: Grant/Research Support (Ongoing); Springer Publications: Royalties (Ongoing)
MM

Meggan Mackay, MD, MS

Feinstein Institutes for Medical Research
Manhasset, NY, United States

Disclosure(s): No financial relationships with ineligible companies to disclose

COVID-19 has significantly impacted rheumatology patients and providers with unique considerations for vaccines in immunosuppressed patients. This session will address vaccine efficacy in patients with rheumatic diseases and vascular manifestations of COVID-19.

Learning Objectives:

Describe common vascular manifestations that occur in COVID-19 infections and relevance to rheumatic diseases
Describe appropriate interpretation of autoantibody serologies in the setting of COVID-19 infections and vaccinations
Examine the data related to antibody and T cell responses following COVID-19 vaccines and apply current evidence to vaccines and booster strategies in rheumatic disease patients

Presentations:

12:00 PM – 12:20 PM Eastern Time

Vaccines for Immunosuppressed Patients
Speaker: Judith James, MD, PhD – Oklahoma Medical Research Foundation
12:20 PM – 12:40 PM Eastern Time

COVID-19 Lessons from Pathology: Labs to Vasculopathy
Speaker: Cynthia Magro, MD – Weill Cornell Medicine
12:40 PM – 1:00 PM Eastern Time

Q&A